300584Hicin PharmaceuticalSZSE

Nanjing Hicin Pharmaceutical Co., Ltd.

海辰药业

300584

Shenzhen Stock Exchange

BoardChiNext of Shenzhen Stock Exchange
IndustryPharmaceutical Manufacturing
ListedJanuary 12, 2017
Websitewww.hicin.cn
IR Emailir@hicin.cn
Phone(+86)25-83241873
AddressNo. 1, Hengfa Road, Economic and Technological Development Zone, Nanjing, Jiangsu

Company Profile

1. Advantage in R&D capabilities The company adheres to the core strategy of new drug research and development for its growth. Since its establishment, it has set up a research and development center, with over 60 R&D personnel dedicated to drug research and development. The company is equipped with advanced domestic scientific research equipment and analytical instruments, and has established a complete R&D system. The company and its affiliated parties are still significant shareholders of the NMS Group at present. 2. Product category advantages The company currently holds 79 approval numbers for active pharmaceutical ingredients and preparations, with over 20 products in operation all year round. The products cover multiple fields such as cardiovascular and cerebrovascular drugs, antibiotics, diuretics, digestive drugs, antiviral drugs, and immunomodulatory drugs. 3. Advantages in drug quality The company attaches great importance to product quality and has always adhered to the quality policy of "Quality First, Full Participation, Risk Management, standardized production, continuous improvement, and Safe Medication Use". 4. Advantages of marketing network At present, the company's marketing network has covered major provinces and provincial capitals, as well as key cities with independent planning status across the country. It has over 1,000 distributors nationwide, and its products are sold in approximately 3,000 hospitals at or above the county level. 5. Industrial synergy advantages The wholly-owned subsidiaries Zhenjiang Derui and Anhui Haichen, as well as the holding subsidiary Anqing Huichen, are important strategic layouts for the company to achieve industrial chain synergy and integration. They not only ensure the sufficient supply of raw materials for various varieties of the company's subsequent product lines but also strengthen the company's management of raw material prices and product gross profit margins, reducing the potential risks brought by the future supply chain to the company's operations. It has profound significance for the company's layout of the entire industrial chain of chemical pharmaceuticals and battery materials. 6. Advantage of resource integration The company's founder, senior executives and expert team have been deeply involved in the pharmaceutical industry for over three decades. They possess a professional background in the pharmaceutical field, have a keen insight and judgment into the industry's development trends, and have rich resources and information advantages in the pharmaceutical industry. They are capable of integrating resources in line with industry policies and market changes to formulate the company's development strategy.

Full description

The company and its subsidiaries are mainly engaged in the research and development, production and sales of chemical preparations, active pharmaceutical ingredients and intermediates. The company's product range is rich and the structure is reasonable, with main products covering treatment areas such as cardiovascular and cerebrovascular diseases, diuresis, anti-infection, digestive system, immune regulation, hypoglycemic, orthopedics, etc. The company adheres to the development of innovative and high-quality products with clinical value, and has a total of 79 approved numbers or registration numbers for preparations and active pharmaceutical ingredients. The main products have been included in the National Medical Insurance Catalogue for 2025. Through professional evidence-based medical promotion, the company meets the needs of a large number of patients.

Announcements

0 total
No announcements match your search.